STOCKWATCH: The ugly sisters of biotech
This article was originally published in Scrip
Executive Summary
Ask almost any hedge fund manager and you'll find that they seem to have many more short ideas than long ones. That means that they have identified more companies that they think are likely to fail resulting in their share prices going down, than those who are doing everything right and are likely to succeed. However, it's a lot harder to predict the stock market performance of the biotech sector as a whole because it is impossible to predict when the market forces that have resulted in the recent biotech bubble – algorithmic trading and the interest of generalist investors – will fade away.
You may also be interested in...
Stock Watch: Is Johnson & Johnson Edging Away From Pharma?
J&J’s Medtech division outshone pharma while recently launched innovative products contributed minimally: it is to be hoped investors’ reactions to the first set of big pharma Q1 results will not set the tempo for earnings season.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.